Key Developments: AMAG Pharmaceuticals Inc (AMAG.O)

AMAG.O on Nasdaq

43.50USD
11:44am EST
Price Change (% chg)

$-0.67 (-1.52%)
Prev Close
$44.17
Open
$44.17
Day's High
$44.81
Day's Low
$43.30
Volume
170,826
Avg. Vol
590,782
52-wk High
$44.81
52-wk Low
$16.49

Search Stocks

Latest Key Developments (Source: Significant Developments)

AMAG Pharmaceuticals completes acquisition of Lumara Health's Maternal Health Business
Wednesday, 12 Nov 2014 04:00pm EST 

AMAG Pharmaceuticals Inc:Completed the acquisition of Lumara Health Inc., a specialty pharmaceutical company with a particular focus on maternal health.Says the transaction was announced on Sept. 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration of up to $350 million based on the achievement of sales milestones.  Full Article

AMAG Pharmaceuticals to acquire Lumara Health Maternal Health Business; gives FY 2015 guidance
Monday, 29 Sep 2014 06:55am EDT 

AMAG Pharmaceuticals Inc:To acquire Lumara Health Inc., a privately-held pharmaceutical company specializing in women's health, for $675 mln ($600 mln in cash and $75 mln in stock) and additional contingent consideration of up to $350 mln based on achievement of certain sales milestones.Transaction is expected to result in projected combined FY 2015 product sales of $350 mln and is expected to be immediately accretive to adjusted earnings per share, with cost synergies of at least $20 mln per year.  Full Article

AMAG Pharmaceuticals Inc raises FY 2014 revenue guidance; lowers FY 2014 net income guidance
Tuesday, 29 Jul 2014 07:00am EDT 

AMAG Pharmaceuticals Inc:Increases FY 2014 total revenue guidance of between $93 mln and $102 mln, including U.S. Feraheme net product sales of $80 mln to $87 mln, revised upward from the company's previous estimate of $75 mln to $85 mln.Increases FY 2014 net loss guidance to $12 mln to $14 mln from the company's previous estimate of $10 mln to $12 mln.FY 2014 revenue of $94 mln and net income of $(0.6) mln - Thomson Reuters I/B/E/S.  Full Article

AMAG Pharmaceuticals Inc announces publication of data from a multi-institutional trial of MuGard
Monday, 28 Apr 2014 08:00am EDT 

AMAG Pharmaceuticals Inc:Says the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available on April 28.MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa.Randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.No difference in adverse effects was observed between patients receiving MuGard and those patients receiving the saline-bicarbonate control.No patients discontinued MuGard because of an adverse effect while two patients using the sham-control discontinued due to nausea or vomiting.  Full Article

AMAG Pharmaceuticals, Inc reaffirms FY 2014 revenue guidance; issues FY 2014 earnings guidance below analysts' estimates
Thursday, 24 Apr 2014 07:03am EDT 

AMAG Pharmaceuticals, Inc:Expects FY 2014 total revenues of between $88 mln and $100 mln.Expects FY 2014 net loss (GAAP) in the range of $10 mln to $12 mln.Expects FY 2014 positive adjusted EBITDA (non-GAAP) of $10 mln to $13 mln.FY 2014 revenue of $95 mln, net income of $(1.08) mln and EBITDA of $(1.97) mln - Thomson Reuters I/B/E/S.  Full Article

AMAG Pharmaceuticals announces transition of chairman role to Gino Santini
Wednesday, 16 Apr 2014 05:00pm EDT 

AMAG Pharmaceuticals, Inc:Says its current board member, Gino Santini, has been elected, to Chairman of the board of directors, effective immediately, taking over for Mike Narachi.  Full Article

AMAG Pharmaceuticals Inc announces pricing of $175 mln of 2.50% convertible senior notes due 2019
Wednesday, 12 Feb 2014 06:00am EST 

AMAG Pharmaceuticals Inc:Says the pricing of $175 mln aggregate principal amount of 2.50% convertible senior notes due in an underwritten public offering registered under the Securities Act of 1933, as amended.The size of the transaction was increased from the previously announced aggregate principal amount of $150 mln.J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers and Cowen and Company, LLC and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering.The company has granted the underwriters the option to purchase, exercisable within a 30-day period, up to an additional $25 mln principal amount of notes solely to cover over-allotments, if any.The offering is expected to close on Feb 14.Interest on the notes will be paid semiannually in arrears on Feb 15 and Aug 15 of each year at the rate of 2.50% per year, beginning on Aug 15.Estimates that the net proceeds from the offering of the notes will be about $169.1 mln (or about $193.3 mln if the underwriters exercise their over-allotment option in full).Expects to use a portion of the net proceeds from the offering of the notes to pay the cost of the convertible note hedge transactions.Intends to use the remainder of the net proceeds from the offering for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.  Full Article

AMAG Pharmaceuticals Inc announces proposed offering of $150 mln of convertible senior notes due 2019
Monday, 10 Feb 2014 04:07pm EST 

AMAG Pharmaceuticals Inc:Intends to offer, subject to market and other conditions, $150 mln aggregate principal amount of convertible senior notes due 2019 in an underwritten public offering registered under the Securities Act of 1933, as amended.J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers for the offering.Expects to grant the underwriters an option to purchase, exercisable within a 30-day period, up to an additional $22.5 mln principal amount of notes, solely to cover over-allotments, if any.Says notes will pay interest semiannually and will mature on Feb. 15, 2019, unless earlier repurchased or converted in accordance with their terms prior to such date.Says it will not have the right to redeem the notes prior to maturity.Says prior to May 15, 2018, the notes will be convertible at the option of holders of the notes only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.Says upon conversion, holders of the notes will receive shares of AMAG's common stock, cash or a combination thereof, at AMAG's election.Says interest rate, initial conversion rate and other terms of the notes will be determined by negotiations between AMAG and the underwriters of the notes at the time of the pricing of the offering.  Full Article

AMAG Pharmaceuticals Inc issues FY 2014 revenue guidance below analysts' estimates
Thursday, 6 Feb 2014 07:00am EST 

AMAG Pharmaceuticals Inc:Expects FY 2014 revenue to be in the range of $88 mln and $100 mln (not including the potential milestone payment for broad IDA approval in the E.U.).Expects FY 2014 revenue of $108 mln - Thomson Reuters I/B/E/S.  Full Article

AMAG Pharmaceuticals Inc announces issuance of new U.S. Patent for Ferumoxytol
Friday, 31 Jan 2014 08:30am EST 

AMAG Pharmaceuticals Inc:Says United States Patent and Trademark Office has issued a new U.S. patent to AMAG for ferumoxytol, U.S. Patent No. 8,591,864, Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents, expiring in Mar. 2020.Says this patent is listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the United States Food and Drug Administration.  Full Article

Amag Pharma enters women health business with $675 million deal

- Amag Pharmaceuticals Inc entered the women's healthcare business by acquiring privately held Lumara Health Inc for $675 million in its biggest deal ever, sending its shares up as much as 23 percent to a four-year high.

Search Stocks